Dr. Omalley On Research With Immunotherapy In Ovarian Cancer

Dr. O’Malley on Research With Immunotherapy in Ovarian Cancer

Dr. O’Malley on the State of Immunotherapy in Ovarian Cancer

Dr. O’Malley on Ongoing Clinical Trials Evaluating Immunotherapy in Ovarian Cancer

Dr. O’Malley on the Utility of Mirvetuximab in Ovarian Cancer

Dr. O’Malley on Antitumor Activity With Veliparib Combo in Serous Ovarian Cancer

Dr. O’Malley on the FORWARD II Phase Ib Study in Ovarian Cancer

Dr. O’Malley on Remaining Questions in Ovarian Cancer

Dr. O’Malley on the Optimal Use of PARP Inhibitors in Advanced Ovarian Cancer

Impact of Cancer & Symptom Management, Female-Bodied (Sexual Health & Cancer Survivorship Series)

NYU Langone Health

Research to Advance Immunotherapy for Ovarian Cancer

Stanford Health Care

Dr. O’Malley on the Safety Profile of Mirvetuximab in Ovarian Cancer

Results for Combination Bevacizumab Plus Mirvetuximab Soravtansine in Ovarian Cancer

Targeted Oncology

Dr. Moore on Challenges With Immunotherapy in Ovarian Cancer

Dr. O’Malley on the Activity of Mirvetuximab Soravtansine in Ovarian Cancer

Patient Immunotherapy Summit: Ovarian Cancer Brief

Cancer Research Institute

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

Immunotherapy & ovarian cancer

Ovarian Cancer Action UK

Dr. Hays on Immunotherapy in Ovarian Cancer Treatment

Dr. Coleman on Immunotherapy in Ovarian Cancer

Dr. O'Malley on Toxicity Profiles of PARP Inhibitors in Ovarian Cancer